Rich countries represent only 13 per cent of the entire world. And they have already ensured more than half of the proposed supply of corona vaccines with different stages of development. Some of those countries have booked five doses for each citizen, whereas the requirement is only two doses.
With the encouraging results of trial testing of Kovid-19 vaccines by two major pharma companies in the US, the challenge for the developing world is to design a vaccination program for its densely populated population. There is also pressure because large quantities of top vaccine can be stored by rich countries.
Moderna announced that its vaccine candidate is about 95 percent effective, while Pfizer has declared it to be 90 percent effective in its candidate trials developed with BioNotech.
By the time this report is written, the Kovid-19 epidemic has infected 53 million people in the world, more than one million people have died.
Both pharma companies released their results not in Peer-Reviewed Journals (equivalent reviewed journals) but through press statements. However, these announcements have been taken up by international health experts.
US virus expert Dr. Anthony Fossey said, “Now we have two vaccines which are really quite effective. So I think this is really a strong step in the direction where we want to control this outbreak.”
Both Moderna and Pfizer used innovative technology to design their vaccines.
Zoltan Kiss, a research associate at Imperial College, London, said, “So this technique involves RNA, which is a molecule that provides information on the formation of antigens to the body’s cells.”
In layman’s language, this concept refers to injecting part of the genetic code of the coronovirus into the body, which trains the immune system to attack, thereby trying to ward off the real virus.
Storage, availability, constraints
But there is one factor that can complicate the future of Moderna and Pfizer’s vaccines, and their storage and widespread availability. Especially in low income areas with hot climate. Both vaccines require low temperatures – minus 20 Celsius for Moderna and ultra-cold storage of up to minus 75 Celsius for Pfizer.
Health experts in India specifically describe the feasibility of Pfizer’s vaccine as difficult.
AIIMS director Randeep Guleria said, “The Pfizer vaccine has to be kept at -70 ° C, which is a challenge for developing countries like India, where we will find it difficult to maintain cold chains, especially in rural missions.”
Guleria, however, described it as an encouraging development for vaccine research.
Explain that rich countries represent only 13 percent of the whole world. And they have already ensured more than half of the proposed supply of vaccines with different stages of development.
Some of those countries have booked five doses for each citizen, whereas the requirement is only two doses. This is a step that shows the danger of creating a supply crisis for the developing world.
Mordana CEO Stephen Bansell said, “The first agreement we had with the US government was for 100 million dose orders. Therefore, we estimate that up to 20 million of those 100 million before the year was over.” We will be able to shipping. ”
What is the situation of India?
India’s vaccine community has already partnered with several indigenous and international stakeholders to develop the Kovid-19 vaccine with various new technologies.
VK Paul, head of Expert Group on Vaccine, told Aaj Tak / India Today, “India is very fortunate that we have a very broad industrial base for vaccine manufacturing and we also have a research and development setup for vaccine development. Also there is a regulatory system which is very strong. ”
Vaccine Program in India
In the country, India Biotech vaccine candidate is in Phase III trial in collaboration with ICMR. The same situation is with the Oxford-AstraZeneca vaccine being developed in collaboration with the Serum Institute of India.
AstraZeneca aims to produce 100 million doses by December.
Dr. Paul pointed out that Russia’s Candidate Sputnik is also expected to undergo human trials in India next week. The Candidate of Zydus Cadila is expected to enter the critical third phase by December and be ready by March next year. It has in-house capacity to produce 100 million doses.
Dr. Paul said, “I think if we are taking an optimistic view then it is possible that this will be a reality in the early part of 2021. However, this should coincide with caution.”
Dr. Pal continued, “So we are hopeful, we are ahead of the curve and we are preparing.”
Dr. Shekhar C. Mande, Director General of Council of Scientific and Industrial Research (CSIR) expressed similar views as Dr. Pal. He told Aaj Tak / India Today, “Indian vaccine manufacturers are doing well, we should expect something by early next year. Whenever in the world